$RGBP
Regen BioPharma Inc

2024 Q3 Form 8-K Financial Statement

#000149315224048090 Filed on November 29, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024
Revenue $236.6K
YoY Change 86.92%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $0.00
YoY Change -100.0%
% of Gross Profit
Research & Development $153.7K
YoY Change -27.61%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $153.7K
YoY Change -27.61%
Operating Profit -$418.2K
YoY Change -39.12%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$449.1K
YoY Change -124.36%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$264.9K -$867.3K
YoY Change -18.5% -174.99%
Net Earnings / Revenue -366.61%
Basic Earnings Per Share -$0.21
Diluted Earnings Per Share -$0.21
COMMON SHARES
Basic Shares Outstanding 4.508M shares 4.110M shares
Diluted Shares Outstanding 4.110M shares

Balance Sheet

Concept 2024 Q3 2024
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $716.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables $94.87K
Other Receivables
Total Short-Term Assets $159.9K
YoY Change 22.01%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $17.73K
YoY Change -92.03%
Other Assets
YoY Change
Total Long-Term Assets $17.73K
YoY Change -92.03%
TOTAL ASSETS
Total Short-Term Assets $159.9K
Total Long-Term Assets $17.73K
Total Assets $177.6K
YoY Change -49.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $29.67K
YoY Change -0.02%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.372M
YoY Change 1.2%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.372M
Total Long-Term Liabilities $0.00
Total Liabilities $5.372M
YoY Change -1.58%
SHAREHOLDERS EQUITY
Retained Earnings -$20.62M
YoY Change 4.39%
Common Stock $527.00
YoY Change 49.72%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$5.194M
YoY Change
Total Liabilities & Shareholders Equity $177.6K
YoY Change -49.77%

Cashflow Statement

Concept 2024 Q3 2024
OPERATING ACTIVITIES
Net Income -$264.9K -$867.3K
YoY Change -18.5% -174.99%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$693.1K
YoY Change 298.55%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $563.7K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $572.8K
YoY Change 135.0%
NET CHANGE
Cash From Operating Activities -$693.1K
Cash From Investing Activities
Cash From Financing Activities $572.8K
Net Change In Cash -$120.3K
YoY Change -272.3%
FREE CASH FLOW
Cash From Operating Activities -$693.1K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024 dei Document Type
DocumentType
8-K
CY2024 dei Amendment Flag
AmendmentFlag
false
CY2024 dei Entity Registrant Name
EntityRegistrantName
REGEN BIOPHARMA, INC.
CY2024 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2024 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-5192997
CY2024 dei Entity File Number
EntityFileNumber
333-191725
CY2024 dei Entity Address Address Line1
EntityAddressAddressLine1
4700 Spring Street
CY2024 dei Entity Address Address Line2
EntityAddressAddressLine2
St 304
CY2024 dei Entity Address City Or Town
EntityAddressCityOrTown
La Mesa
CY2024 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2024 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
91942
CY2024 dei City Area Code
CityAreaCode
(619)
CY2024 dei Local Phone Number
LocalPhoneNumber
722 5505
CY2024 dei Written Communications
WrittenCommunications
false
CY2024 dei Soliciting Material
SolicitingMaterial
false
CY2024 dei Pre Commencement Tender Offer
PreCommencementTenderOffer
false
CY2024 dei Pre Commencement Issuer Tender Offer
PreCommencementIssuerTenderOffer
false
CY2024 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024 dei Entity Central Index Key
EntityCentralIndexKey
0001589150
CY2024 dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
716 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
94873 usd
CY2024Q3 RGBP Prepaid Expenses Current
PrepaidExpensesCurrent
59289 usd
CY2024Q3 us-gaap Prepaid Rent
PrepaidRent
5000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
159878 usd
CY2024Q3 us-gaap Equity Method Investments
EquityMethodInvestments
17733 usd
CY2024Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
17733 usd
CY2024Q3 us-gaap Assets
Assets
177611 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
29669 usd
CY2024Q3 us-gaap Notes Payable Current
NotesPayableCurrent
293819 usd
CY2024Q3 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
4241 usd
CY2024Q3 us-gaap Interest Payable Current
InterestPayableCurrent
362533 usd
CY2024Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1256630 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
41423 usd
CY2024Q3 us-gaap Bank Overdrafts
BankOverdrafts
1000 usd
CY2024Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1397274 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5371640 usd
CY2024Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
0 usd
CY2024Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
0 usd
CY2024Q3 us-gaap Liabilities
Liabilities
5371640 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5800000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5258235 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5258235 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3506366 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3506366 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
527 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
800000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
800000000 shares
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
14684216 usd
CY2024Q3 us-gaap Other Additional Capital
OtherAdditionalCapital
736326 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-20616114 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-5194029 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
177611 usd
CY2023Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1 for 1500
CY2024 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
236560 usd
CY2024 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
153685 usd
CY2024 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
58922 usd
CY2024 us-gaap Professional Fees
ProfessionalFees
364927 usd
CY2024 RGBP Rent
Rent
77215 usd
CY2024 us-gaap Costs And Expenses
CostsAndExpenses
654749 usd
CY2024 us-gaap Operating Income Loss
OperatingIncomeLoss
-418189 usd
CY2024 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
72445 usd
CY2024 RGBP Interest Expense Attributable To Amortrization Of Discount
InterestExpenseAttributableToAmortrizationOfDiscount
28998 usd
CY2024 us-gaap Debt Securities Unrealized Gain Loss
DebtSecuritiesUnrealizedGainLoss
-204847 usd
CY2024 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
2726 usd
CY2024 us-gaap Legal Fees
LegalFees
145500 usd
CY2024 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-449063 usd
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-867252 usd
CY2024 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-867252 usd
CY2024 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2024 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2024 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4110265 shares
CY2024 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4110265 shares
CY2023Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1 for 1500
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-5104000 usd
CY2023Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
22726 usd
CY2023Q4 RGBP Stock Issued During Period Value New Issues One
StockIssuedDuringPeriodValueNewIssuesOne
46091 usd
CY2023Q4 RGBP Stock Issued During Period Value New Issues Two
StockIssuedDuringPeriodValueNewIssuesTwo
38205 usd
CY2023Q4 RGBP Stock Issued During Period Value New Issues Three
StockIssuedDuringPeriodValueNewIssuesThree
32629 usd
CY2023Q4 RGBP Stock Issued During Period Value New Issues Four
StockIssuedDuringPeriodValueNewIssuesFour
38101 usd
CY2023Q4 RGBP Stock Issued During Period Value New Issues Five
StockIssuedDuringPeriodValueNewIssuesFive
34543 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-349760 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-5241463 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
39638 usd
CY2024Q1 RGBP Stock Issued During Period Value New Issues One
StockIssuedDuringPeriodValueNewIssuesOne
44297 usd
CY2024Q1 RGBP Stock Issued During Period Value New Issues Two
StockIssuedDuringPeriodValueNewIssuesTwo
19614 usd
CY2024Q1 RGBP Stock Issued During Period Value New Issues Three
StockIssuedDuringPeriodValueNewIssuesThree
32362 usd
CY2024Q1 RGBP Stock Issued During Period Value New Issues Four
StockIssuedDuringPeriodValueNewIssuesFour
25282 usd
CY2024Q1 RGBP Stock Issued During Period Value New Issues Five
StockIssuedDuringPeriodValueNewIssuesFive
26781 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-122473 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-5175963 usd
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
25326 usd
CY2024Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
13044 usd
CY2024Q2 RGBP Stock Issued During Period Value New Issues One
StockIssuedDuringPeriodValueNewIssuesOne
30000 usd
CY2024Q2 RGBP Stock Issued During Period Value New Issues Two
StockIssuedDuringPeriodValueNewIssuesTwo
30000 usd
CY2024Q2 RGBP Stock Issued During Period Value New Issues Three
StockIssuedDuringPeriodValueNewIssuesThree
50000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-130120 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-5157712 usd
CY2024Q3 RGBP Preferred Shares Distributed As Dividend
PreferredSharesDistributedAsDividend
0 usd
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
28126 usd
CY2024Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
145500 usd
CY2024Q3 RGBP Stock Issued During Period Value Issued For Services One
StockIssuedDuringPeriodValueIssuedForServicesOne
54956 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-264899 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-5194029 usd
CY2023Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1 for 1500
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-867252 usd
CY2024 us-gaap Share Based Compensation
ShareBasedCompensation
5876 usd
CY2024 RGBP Share Based Compensation For Common Stock
ShareBasedCompensationForCommonStock
3036 usd
CY2024 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
28998 usd
CY2024 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
145500 usd
CY2024 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5 usd
CY2024 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
94874 usd
CY2024 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
19946 usd
CY2024 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-5200 usd
CY2024 RGBP Increasedecrease In Contributed Capital
IncreasedecreaseInContributedCapital
-0 usd
CY2024 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-2726 usd
CY2024 us-gaap Increase Decrease In Unearned Premiums
IncreaseDecreaseInUnearnedPremiums
-141687 usd
CY2024 us-gaap Debt Instrument Decrease Forgiveness
DebtInstrumentDecreaseForgiveness
0 usd
CY2024 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-204847 usd
CY2024 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-693141 usd
CY2024 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
10000 usd
CY2024 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
19133 usd
CY2024 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
563686 usd
CY2024 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
572819 usd
CY2024 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-120322 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
121037 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
715 usd
CY2024 RGBP Cash Paid For Interest
CashPaidForInterest
17500 usd
CY2023Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1 for 1500
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0474 pure
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
11.4286 pure
CY2024 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
1 pure
CY2023 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
0 usd
CY2024 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
0 usd
us-gaap Net Income Loss
NetIncomeLoss
20616114 usd
CY2017Q2 RGBP Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Percentage
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsPercentage
0.10 pure
CY2017Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
75
CY2017Q4 RGBP Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Percentage
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsPercentage
0.10 pure
CY2017Q4 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
37.5
CY2017Q4 RGBP Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Percentage
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsPercentage
0.10 pure
CY2017Q4 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
37.5
CY2024Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
0 usd
CY2022Q1 us-gaap Debt Instrument Periodic Payment
DebtInstrumentPeriodicPayment
5000 usd
CY2022Q1 us-gaap Payments For Rent
PaymentsForRent
5000 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5800000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5258235 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5258235 shares
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
800000000 shares
CY2023Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
16710 shares
CY2023Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
22726 usd
CY2023Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
35785 shares
CY2023Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
46091 usd
CY2023Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
31732 shares
CY2023Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
38205 usd
CY2023Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
33989 shares
CY2023Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
32629 usd
CY2023Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
43297 shares
CY2023Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
38101 usd
CY2023Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
82686 shares
CY2023Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
34543 usd
CY2024Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
94883 shares
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
39638 usd
CY2024Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
82643 shares
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
44297 usd
CY2024Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
40229 shares
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
19614 usd
CY2024Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
52569 shares
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
32362 usd
CY2024Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
44503 shares
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
25282 usd
CY2024Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
49230 shares
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
26781 usd
CY2024Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
52763 shares
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
25326 usd
CY2024Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
66185 shares
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
30000 usd
CY2024Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
62207 shares
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
30000 usd
CY2024Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
75301 shares
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
50000 usd
CY2024Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
135242 shares
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
28126 usd
CY2024Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
500000 shares
CY2024Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
250000 usd
CY2024Q3 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
4329384 usd
CY2024Q3 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
-0 usd
CY2024Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
4329384 usd
CY2024Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
4329384 usd
CY2024Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
-0 usd
CY2024Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
4329384 usd
CY2024Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
20616114 usd
CY2024 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.50 pure
CY2024Q3 us-gaap Operating Loss Carryforwards Valuation Allowance
OperatingLossCarryforwardsValuationAllowance
0 usd

Files In Submission

Name View Source Status
0001493152-24-048090-index-headers.html Edgar Link pending
0001493152-24-048090-index.html Edgar Link pending
0001493152-24-048090.txt Edgar Link pending
0001493152-24-048090-xbrl.zip Edgar Link pending
ex99-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form8-k.htm Edgar Link pending
MetaLinks.json Edgar Link pending
form8-k_htm.xml Edgar Link completed
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rgbp-20240930.xsd Edgar Link pending
Show.js Edgar Link pending
rgbp-20240930_def.xml Edgar Link unprocessable
rgbp-20240930_cal.xml Edgar Link unprocessable
rgbp-20240930_lab.xml Edgar Link unprocessable
rgbp-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable